Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation

Experimental Neurology

Volumn 154, Issue 2, 1998, Pages 464-472

  Burkhart, Keith K ^a   Beard, Daniel C ^a   Lehman, Ralph A W ^a   Billingsley, Melvin L ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Cytoskeleton; Ischemic stroke; Okadaic acid; Tau

Indexed keywords

GLUCOSE; LUBELUZOLE; OKADAIC ACID; TAU PROTEIN;

ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; BRAIN SLICE; CONTROLLED STUDY; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; MALE; MICROTUBULE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

EID: 0032409926     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6899     Document Type: Article

References (23)

1. Aston D., Willems R., Wynants J., Van Reempts J., Marrannes J., Clinke G. Altered Na-channel function as an in vitro model of the ischemic penumbra: Action of lubeluzole and other neuroprotective drugs. Brain Res. 745:1997;210-221.
2. Au K., Gurd J. W. Tyrosine phosphorylation in a model of ischemia using the rat hippocampal slice: Specific long-term decrease in the tyrosine phosphorylation of the postsynaptic glycoprotein PSD-GP180. J. Neurochem. 65:1995;1834-1841.
3. Billingsley M. L., Kincaid R. L. Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323:1997;577-591.
4. De Ryck M. Protection of neurological function in stroke models and neuroprotective properties of lubeluzole. Cerebrovasc. Dis. 7:1997;18-30.
5. Dewar D., Dawson D. Tau protein is altered by focal cerebral ischemia in the rat: An immunohistochemical and immunoblotting study. Brain Res. 684:1995;70-78.
6. Diener H. C., Hacke W., Hennerici M., Radberg J., Hantson L., De Keyser J. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke. 27:1996;76-81.
7. Djuricic B., Berger R., Paschen W. Protein synthesis and energy metabolism in hippocampal slices during extended (24 hours) recovery following different periods of ischemia. Metab. Brain Dis. 9:1994;377-389.
8. Garver T. D., Oyler G. A., Harris K. A., Polavarapu R., Damuni Z., Lehman R. A. W., Billingsley M. L. Tau phosphorylation in brain slices: Pharmacologic evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. Mol. Pharmacol. 47:1995;745-756.
9. Garver T. D., Lehman R. A. W., Lee V. M.-Y., Trojanowski J. Q., Billingsley M. L. Tau phosphorylation in human, primate and rat brain: Evidence that a pool of tau is highly phosphorylatedin vivoin vitro. J. Neurochem. 63:1994;2279-2287.
10. Geddes J. W., Schwab C., Craddock S., Wilson J. L., Pettigrew L. C. Alterations in tau immunostaining in the rat hippocampus following transient cerebral ischemia. J. Cereb. Blood Flow Metab. 14:1994;554-564.
11. Irving E. A., Nicoll J., Graham D. I., Dewar D. Increased tau immunoreactivity in oligodendrocytes following human stroke and head injury. Neurosci. Lett. 213:1996;189-192.
12. Kral T., Luhman H. J., Mittmann T., Heinemann U. Role of NMDA receptors and voltage-activated calcium channels in an in vitro model of cerebral ischemia. Brain Res. 612:1993;278-288.
13. Kusumoto M., Dux E., Paschem W., Hossmann K.-A. Susceptibility of hippocampal and cortical neurons to argon-mediatedin vitro. J. Neurochem. 67:1996;1613-1621.
14. Mitani A., Yanase H., Namba S., Shudo M., Kataika K. In vitro. Acta Neuropathol. 89:1995;2-7.
15. Paschen W., Djuricic B. Comparison ofin vitro. J. Neurochem. 65:1995;1692-1697.
16. Pringle A. K., Iannotti F., Wilde G. J. C., Chad J. E., Seeley P. J., Sundstrom L. E. Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia. Brain Res. 155:1997;36-46.
17. Roettger V., Lipton P. Mechanism of glutamate release from rat hippocampal slices duringin vitro. Neuroscience. 75:1996;677-685.
18. Shackelford D. A., Nelson K. E. Changes in phosphorylation of tau during ischemia and reperfusion in the rabbit spinal cord. J. Neurochem. 1996;286-295.
19. Sindou P., Couratier P., Barthe D., Hugon J. A dose-dependent increase of Tau immunostaining is produced by glutamate toxicity in primary neuronal cultures. Brain Res. 572:1992;242-246.
20. Tymianski M., Wallace M. C., Spiegelman I., Uno M., Carlen P. L., Tator C. H., Charlton M. P. Cell-permeant Ca+2-chelators reduce early excitotoxic and ischemic neuronal injuryin vitroin vivo. Neuron. 11:1993;221-235.
21. Uchihara T., Tsuchiya K., Kondo H., Hayama T., Ikeda K. Widespread appearance of Alz-50 immunoreactive neurons in the human brain with cerebral infarction. Stroke. 26:1995;2145-2148.
22. Vornov J. J., Tasker R. C., Coyle J. T. Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia. Stroke. 25:1994;457-465.
23. Zini S., Roisin M.-P., Armengaud C., Ben-Ari Y. Effect of potassium channel modulators on the release of glutamate induced by ischemic-like conditions in rat hippocampal slices. Neurosci. Lett. 153:1993;202-205.